As pharma marketers, we strive to be patient-centric. We create and analyze patient journeys, conduct in-depth research, and even co-create materials, all with the focus of creating personalized, engaging campaigns that empower and educate patients. Sometimes, though, the science takes a leap of such breadth and scale that it changes the very concept and meaning of patient-centricity.
Five patients with systemic lupus erythematosus (SLE) are in remission after receiving CAR T cell therapy, according to a study published Thursday in Nature Medicine.
With $165 million in the bank, Capstan Therapeutics launched Wednesday to combine the potency of cell therapy with the precision of genetic medicines against various difficult-to-treat diseases.
Roche signed a $6 billion-plus collaboration deal with Poseida Therapeutics on blood cancers, while its Alzheimer’s partner, AC Immune, parsed failed data on an Alzheimer’s drug to suggest a positive spin.
CAR T therapies have revolutionized oncology patient care. But to ensure the often lifesaving benefits of these therapies reach the right patients, life sciences companies must navigate complex decision-making and treatment processes to maximize uptake.